Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

MLA

Carol Ann Huff, et al. “Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study.” Blood, vol. 128, Dec. 2016, p. 491. EBSCOhost, https://doi.org/10.1182/blood.v128.22.491.491.

APA

Carol Ann Huff, Gregory J. Ahmann, Carla Picklesimer, Cassandra Choe-Juliak, Joshua R. Richter, Ajai Chari, Rachid Baz, Sharon Shacham, James E. Hoffman, Jean-Richard Saint-Martin, Ilsel Lopez, Terri L. Parker, David S. Siegel, Scott VanWier, Craig E. Cole, A. Keith Stewart, Rafael Fonseca, Ajay K. Nooka, R. Frank Cornell, … Divaya Bhutani. (2016). Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. Blood, 128, 491. https://doi.org/10.1182/blood.v128.22.491.491

Chicago

Carol Ann Huff, Gregory J. Ahmann, Carla Picklesimer, Cassandra Choe-Juliak, Joshua R. Richter, Ajai Chari, Rachid Baz, et al. 2016. “Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study.” Blood 128 (December): 491. doi:10.1182/blood.v128.22.491.491.